UK Markets close in 4 hrs 55 mins
  • FTSE 100

    7,144.07
    +14.86 (+0.21%)
     
  • FTSE 250

    22,776.07
    +91.23 (+0.40%)
     
  • AIM

    1,191.34
    +2.60 (+0.22%)
     
  • GBP/EUR

    1.1737
    -0.0029 (-0.25%)
     
  • GBP/USD

    1.3268
    -0.0034 (-0.2587%)
     
  • BTC-GBP

    42,986.33
    +295.76 (+0.69%)
     
  • CMC Crypto 200

    1,456.76
    +17.87 (+1.24%)
     
  • S&P 500

    4,577.10
    +64.06 (+1.42%)
     
  • DOW

    34,639.79
    +617.75 (+1.82%)
     
  • CRUDE OIL

    67.89
    +1.39 (+2.09%)
     
  • GOLD FUTURES

    1,772.70
    +10.00 (+0.57%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • DAX

    15,257.38
    -5.73 (-0.04%)
     
  • CAC 40

    6,789.03
    -6.72 (-0.10%)
     
Markets:

European stock markets push higher as Omicron strain concerns ease

Coloplast A/S - Announcement no. 07/2021 – Annual Report 2020/21 & Remuneration Report 2020/21

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Financial highlights for the year 2020/21

  • Coloplast delivered 7% organic growth for the full year. Reported revenue in DKK was up by 5% to DKK 19,426 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 5%, Interventional Urology 19%, Wound & Skin Care 8%.

  • EBIT before special items amounted to DKK 6,355 million, a 9% increase from last year, corresponding to an EBIT margin before special items of 33% against 32% last year, reflecting efficiency gains and lower spending due to COVID-19 offset by commercial investments.

  • ROIC after tax before special items was 45% against 46% last year, negatively impacted by the acquisition of Nine Continents Medical. Diluted earnings per share (EPS) before special items increased by 19% to DKK 23.36.

  • The Board of Directors recommends a year-end dividend of DKK 14.00 per share, which brings the total dividend for the year to DKK 19.00 per share, compared to DKK 18.00 per share last year.

Financial guidance for 2021/22

  • Organic revenue growth expected around 7% at constant exchange rates. Reported growth in DKK expected around 8%.

  • Reported EBIT margin is expected to be around 32%, impacted by normalization of business activities, raw material price pressure and wage inflation in Hungary and continued commercial investments.

  • Capital expenditures expected to be around DKK 1.2 billion. The effective tax rate is expected to be 22-23% positively impacted by increased R&D cost deductibility which continues in 21/22.


Please find our Annual Report 2020/21 and Remuneration Report 2020/21 in the links below.



For further information, please contact


Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111

Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 /+45 4911 3376
Email: dkebj@coloplast.com

Aleksandra Dimovska
Sr. Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com

Press and the media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com

Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917

Website
www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-11.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting